<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Comparative Analysis</title>
  <link href="https://fonts.googleapis.com/css2?family=Roboto:wght@400;500&display=swap" rel="stylesheet">
  <style>
    body {
      font-family: 'Roboto', sans-serif;
      background-color: #ffffff;
      color: #002855;
      margin: 0;
      padding: 0;
      line-height: 1.6;
    }
    header {
      background-color: #004080;
      color: white;
      padding: 2rem;
      text-align: center;
    }
    h1 {
      margin: 0;
    }
    section {
      max-width: 900px;
      margin: 2rem auto;
      border-left: 5px solid #cc3366;
      padding: 1.5rem 2rem;
      background-color: #f9f9fc;
      border-radius: 8px;
      box-shadow: 0 3px 8px rgba(0, 0, 0, 0.05);
    }
    h2 {
      color: #cc3366;
      margin-top: 0;
    }
    ul {
      padding-left: 1.2rem;
    }
    li {
      margin-bottom: 0.5rem;
    }
    .highlight {
      background-color: #e8f0fe;
      padding: 0.5rem 1rem;
      border-left: 4px solid #004080;
      margin: 1rem 0;
      border-radius: 4px;
    }
  </style>
</head>
<body>
  <header>
    <h1>Comparative Analysis: Spain vs United Kingdom Vaccination Schedules</h1>
  </header>

  <section>
    <h2>Infants (0–3 years)</h2>
    <div class="highlight">
      <strong>Common:</strong> Both use hexavalent vaccines, MenB and rotavirus early in life.
    </div>
    <ul>
      <li><strong>Spain:</strong> PCV given at 6 months, Hib-HepB booster at 11–12 months.</li>
      <li><strong>UK:</strong> PCV at 4 months, Hib/MenC and MenB boosters at 11–12 months.</li>
      <li>MMR timing advanced due to measles outbreaks: UK to 18 months, Spain to 2 years.</li>
    </ul>
  </section>

  <section>
    <h2>Children and Adolescents (3–18 years)</h2>
    <div class="highlight">
      <strong>Shared:</strong> MMR (2nd dose), DTaP/IPV boosters, HPV for boys and girls.
    </div>
    <ul>
      <li><strong>Spain:</strong> MenACWY between 12–14 years, Td at 14 years, routine chickenpox vaccine.</li>
      <li><strong>UK:</strong> Centralized MenACWY and Td/IPV at 14 years; VZV not included.</li>
      <li>Spain recommends flu vaccine up to 18 years (especially 6–59 months).</li>
      <li>UK focuses on delivery via school campaigns.</li>
    </ul>
  </section>

  <section>
    <h2>Adults (19+ years)</h2>
    <ul>
      <li>Both countries provide annual flu and pneumococcal vaccines.</li>
      <li><strong>Spain:</strong> Shingrix at 65 depends on regional approval; RSV not yet routine.</li>
      <li><strong>UK:</strong> Shingrix routine from 65; RSV vaccine from 75 years included.</li>
    </ul>
  </section>

  <section>
    <h2>Pregnant Women</h2>
    <ul>
      <li>Both recommend dTpa and flu vaccine from week 16.</li>
      <li><strong>UK:</strong> Reinforced campaigns post-whooping cough deaths.</li>
      <li><strong>Spain:</strong> Relies on local midwives and healthcare teams.</li>
      <li>Both promote COVID-19 vaccination during pregnancy.</li>
    </ul>
  </section>

  <section>
    <h2>General Comparison</h2>
    <div class="highlight">
      <strong>Spain:</strong> Decentralized model → flexible but unequal implementation.
    </div>
    <div class="highlight">
      <strong>UK:</strong> Centralized model (JCVI) → uniform, efficient national rollouts.
    </div>
    <ul>
      <li>Spain includes broader immunizations (e.g., VZV, MenB in infants).</li>
      <li>UK emphasizes cost-effectiveness and strategic timing.</li>
      <li>Spain anticipates outbreaks; UK focuses on delivery logistics and booster timing.</li>
    </ul>
  </section>
</body>
</html>